Study aim: The effect of Curcuden on RRMS patients will be investigated Design: We randomly divide 68 MS patients into intervention and control groups and we assign a code to each participant. Settings and conduct: This study conduct in the Neurology Research Center of Tehran Imam Khomeini Hospital in double-blind manner. None of the patients are aware that in which group, control or intervention, they are. The doctor also prescribes the medicine as code A and B and no information is available n them about being placebo or medicine. The main neurologist of the project is the only one that is aware of this classification. Participants/Inclusion and exclusion criteria: Inclusion Criteria: RRMS patients who receive first-line treatment drugs for one year but have at least one relapse or active lesion. Meanwhile, at least one month away from the last attack of the disease and the patient's corticosteroid therapy. Patients should be between 18 to 60 years of age with EDSS between 0 and 5.5, and no Curcumin contraindications. Exclusion criteria: Progressive MS patients or patients who have contraindication to use Curcumin or similar substances. The presence of any internal or systemic disease (such as anemia or liver conditions). Every patient is examined by MRI, general and inflammatory factors, once before and once after treatment Intervention groups: The intervention group receive the medication for 6 months at a dose of 180 mg per day. The control group receive placebo for a period of 6 months at a dose of 180 mg. Main outcome variables: The amount of active lesions in the brain and spinal cord and the inflammatory factors of the blood will be compared before and after the treatment between the two groups of test and control. In this way, the efficacy and non-toxicity of the drug will be investigated